Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug Safety Concerns Create CRO Opportunity, PPD Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Contract research organizations could see financial opportunities in "more intricate safety monitoring," CEO Eshelman says during earnings call. Regulatory uncertainty accompanies shift in PPD's business away from big pharma, toward biotech firms.

You may also be interested in...

Takeda Broadens Diabetes Pipeline With PPD Agreement For DPP4 Inhibitors

Takeda completes acquisition of development and marketing rights to PPD’s dipeptidyl peptidase IV inhibitors for treatment of type 2 diabetes. PPD will provide clinical development services. The deal follows the discontinuation of Takeda’s in-house novel diabetes agent due to liver abnormalities.

Savient Delays 10-Q Filing Due To Oxandrin Return Reserve Errors

The firm will restate first quarter and 2004 year-end results due to less-than-expected returns of the anabolic agent.

P&G/Sanofi Combine Actonel With Calcium In 28-Day Regimen

FDA approves bisphosphonate line extension featuring four days of risedronate dosing and 24 days of calcium supplementation.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts